Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...

Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism

Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism

Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...

Pharmacokinetics in Pediatric Patients: Drug Excretion

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...

Pharmacodynamics in Geriatric Patients: Effects of Age

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pharmacokinetic drug evaluation of co-packaged sulbactam for injection and durlobactam for injection for the treatment of <i>Acinetobacter baumannii-calcoaceticus</i> complex in HABP/VABP.

Expert opinion on drug metabolism & toxicology·2025

Same author

Risk of rehospitalization due to <i>Clostridioides difficile</i> infection among hospitalized patients with <i>Clostridioides difficile</i>: a cohort study.

Infection control and hospital epidemiology·2024

Same author

Management and Outcomes of Patients at a Specialty Clinic for <i>Clostridioides difficile</i> Infection.

Open forum infectious diseases·2024

Same author

Commonly Reported Mosquito-Borne Viruses in the United States: A Primer for Pharmacists.

Journal of pharmacy practice·2023

Same author

Pharmacokinetic evaluation of cefiderocol for the treatment of multidrug resistant Gram-negative infections.

Expert opinion on drug metabolism & toxicology·2022

Same author

In vitro activity of imipenem/releactam and comparator agents against clinical bacterial isolates from patients with cancer.

Journal of global antimicrobial resistance·2022

Search research articles

Related Experiment Video

Updated: May 10, 2026

Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing

Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing

Published on: July 7, 2020

Polymyxins: wisdom does not always come with age.

Zahra Kassamali¹, John C Rotschafer, Ronald N Jones

¹Department of Pharmacy Practice, University of Illinois-Chicago, 833 S. Wood St., Chicago, IL 60612, USA.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America

|June 4, 2013

Summary

Polymyxin B potency can vary significantly due to outdated quality control assays, impacting its effectiveness against multidrug-resistant bacteria. Further research is needed to ensure accurate dosing and optimize clinical use of these critical last-line antibiotics.

Keywords:

microbial sensitivity tests polymyxins/pharmacology polymyxins/therapeutic use

More Related Videos

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

Related Experiment Videos

Last Updated: May 10, 2026

Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing

Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing

Published on: July 7, 2020

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

Area of Science:

Pharmacology
Microbiology
Infectious Diseases

Background:

The rise of multidrug-resistant (MDR) bacteria necessitates effective last-line treatments.
Polymyxins are crucial last-line agents for MDR bacterial infections.
Existing literature often assumes accurate polymyxin product purity and potency.

Purpose of the Study:

To review limitations in pharmacological knowledge of polymyxin antimicrobials.
To discuss the clinical impact of these limitations.
To suggest future research for optimizing polymyxin clinical use.

Main Methods:

Literature review focusing on polymyxin pharmacology, purity, and potency.
Analysis of quality assurance assay limitations.
Discussion of clinical implications.

Main Results:

Polymyxin B potency can deviate up to 40% from reported values.
Current quality assurance assays, established in the 1940s, are flawed.
Inaccurate potency affects reliable dosing and clinical outcomes.

Conclusions:

Outdated and flawed quality control assays compromise polymyxin B accuracy.
Significant gaps exist in our understanding of polymyxin pharmacology.
Further investigation is essential to ensure optimal clinical application of polymyxins.